Inhibition by sildenafil of contractility of isolated non-pregnant human myometrium

Aruldhas Blessed Winston, Kaysina Vazhudhi, Sumalya Sen, Elsy Thomas1, Santhosh Benjamin1, Jacob Peedicayil

Department of Pharmacology and Clinical Pharmacology and Obstetrics and Gynaecology, Christian Medical College, Vellore, Tamil Nadu, India

ABSTRACT

Objective: To investigate the ability of sildenafil to inhibit the contractility of isolated non pregnant human myometrium. Materials and Methods: The inhibitory effect of three concentrations (3, 10, and 30 µM) of sildenafil on 55 mM KCl-induced contractility of isolated non-pregnant human myometrium was studied. The ability of the guanylyl cyclase inhibitor ODQ (10 µM), the adenylyl cyclase inhibitor MDL-12,330A (10 µM), the non-specific potassium channel blocker TEA (2 mM), and the calcium-sensitive potassium (BKCa) channel blocker iberiotoxin (100 nM) to reverse the inhibition of 10 µM sildenafil on KCl-induced myometrial contractility was also studied. Results: Sildenafil produced a concentration-dependent inhibition of KCl-induced myometrial contractility that was statistically significant at all three concentrations of sildenafil used. The inhibition by 10 µM sildenafil of KCl-induced myometrial contractility was not reversed by the concurrent administration of ODQ or MDL-12,330A. The inhibition of 10 µM sildenafil of myometrial contractility was partially reversed by concurrent administration of TEA and totally and significantly reversed by the concurrent administration of iberiotoxin. Conclusions: These results suggest that sildenafil inhibits the contractility of isolated non-pregnant human myometrium. The results suggest that sildenafil does so by opening BKCa channels.

Key words: Contractility, myometrium, non-pregnant, sildenafil

INTRODUCTION

Sildenafil is a smooth muscle relaxant which has been approved by the US Food and Drug Administration for the treatment of erectile dysfunction,[1] and pulmonary arterial hypertension.[2] In the former condition it acts by relaxing the corpus cavernosum and in the latter by relaxing the pulmonary artery. It is well established that sildenafil inhibits phosphodiesterase-5 (PDE5), the enzyme that catalyzes the metabolism of the second messenger cyclic GMP.

How to cite this article: Winston AB, Vazhudhi K, Sen S, Thomas E, Benjamin S, Peedicayil J. Inhibition by sildenafil of contractility of isolated non-pregnant human myometrium. J Pharmacol Pharmacother 2015;6:136-41.
Materials and Methods

The study was conducted in two phases. During the first phase, conducted using 10 myometrial strips obtained from 10 patients who underwent hysterectomy, the effects of the vehicle dimethyl sulfoxide (DMSO) and three concentrations of sildenafil (3, 10, and 30 µM) on KCl-induced myometrial contractility were studied. This was followed by studying the ability of the reversal agents 1H-[1,2,4] oxadiazol[4,3-a] quinoxalin-1-one (ODQ, a guanylyl cyclase inhibitor), MDL-12,330A (an adenylyl cyclase inhibitor), and TEA to reverse the inhibitory effect of 10 µM sildenafil on KCl-induced myometrial contractility.

Since the results of the first phase of the study suggested that potassium channels are involved in the inhibitory effect of sildenafil on myometrial contractility, we conducted a second study phase to investigate the ability of the calcium-sensitive potassium (BKCa) channel blocker iberiotoxin to reverse the inhibitory effect of sildenafil. During the second phase of the study, conducted on 10 additional strips obtained from 10 additional patients who underwent hysterectomy, the ability of iberiotoxin to reverse the inhibitory effect of 10 µM sildenafil on KCl-induced myometrial contractility was studied.

Selection of patients

The patients were selected from the Department of Obstetrics and Gynecology, Christian Medical College, Vellore, India.

Inclusion criteria were patients 20 to 50 years of age undergoing hysterectomy for benign conditions like polyps, fibroids, and pelvic organ prolapse. Exclusion criteria were postmenopausal patients and those with malignant conditions. Written informed consent was obtained from each patient included in the study. The study was approved by the Institutional Review Board (IRB minute number 7370 dated 8.12.2010).

Tissue preparation

After removal of the uterus from the patient, parts of the uterus showing gross pathological changes were noted and excluded. A 2 × 2 cm tissue specimen was resected from normal appearing areas of the lateral wall of the uterus. The specimen was then transported in physiological salt solution (PSS) to the pharmacology laboratory within 1 hour. The uterine specimens were examined under a magnifying glass to look for orientation of muscle fibers. Pathological changes like fibroids were also looked for and excluded. The serosa and endometrium were removed from the specimens. Myometrial strips measuring 10 × 3 × 3 mm were then made and mounted in a 20 ml organ bath containing PSS maintained at a temperature of 37°C and adequately aerated with oxygen. The composition of the PSS was in mM: NaCl: 111.5; KCl: 4.6; MgSO₄:1.16; NaH₂PO₄: 1.16; CaCl₂: 2.5; NaHCO₃:21.9; and glucose: 11.1. A resting tension of 25 milliNewtons (mN; about 2.5 g) was applied to the mounted strip.

Drugs

KCl (Qualigens, Mumbai, India) was dissolved in double-distilled water to make a concentration of 168 mg/ml. KCl was prepared fresh before each experiment. Sildenafil (Sigma Aldrich, St Louis, MO, USA) was dissolved in dimethyl sulfoxide (DMSO), (Sigma Aldrich, St Louis, MO, USA) to give a concentration of 5 mg/ml. ODQ (Sigma Aldrich, St Louis, MO, USA) was dissolved in DMSO to give a concentration of 5 mg/ml. MDL-12,330A (Sigma Aldrich, St Louis, MO, USA) in pure powder form was dissolved in DMSO to give a working concentration of 5 mg/ml. TEA (Qualigens, Mumbai, India) was dissolved in double-distilled water to give a concentration of 50 mg/ml. Iberiotoxin (Santa Cruz Biotechnology, Dallas, TX, USA) was dissolved in double-distilled water to give a 4 µM stock solution.

Experimental procedure

Experiments involving effect of sildenafil on KCl-induced contractility of the myometrium

After an equilibration period of 90 minutes, the tension was readjusted to 25 mN. The response of the myometrium to the administration of 55 mM KCl was then studied followed by the response after the administration of 55 mM KCl and 0.25 ml of the solvent used to dissolve sildenafil, DMSO. This was the maximum volume of DMSO used in the study. 55 mM KCl is the standard concentration of KCl used in our laboratory for stimulating the contraction of the isolated myometrium.
We have found this concentration of KCl to be suitable because it is effective and can be washed out easily following muscular contraction. Then 55 mM KCl was administered again. After washing the bath, 55 mM KCl was added again concurrently with the test drug, sildenafil. Three concentrations of sildenafil were used: 3, 10, and 30 µM. The incubation time that was used in the study after administration of the drugs (DMSO, sildenafil, and reversal agents) to the bath was 10 minutes. During each tracing, after drug administration, a contact time of 90 seconds was given, after which the tissue was washed till the baseline was reached. A rest period of 10 minutes was used between drug treatments.

**Experiments involving reversal of inhibitory effect of sildenafil on contractility of the myometrium**

In order to elucidate the mechanism of inhibition of KCl-induced myometrial contractility by sildenafil, the following experimental procedures were performed: KCl was administered alone and then with 10 µM sildenafil and ODQ (10 µM). After washing out the organ bath solution and a rest period, KCl was added alone again, and then with 10 µM sildenafil and MDL-12,330A (10 µM). After washing out the organ bath solution and a rest period, KCl was added alone and then with 10 µM sildenafil and TEA (2 mM).

In the second phase of the study, the ability of the reversal agent iberiotoxin to reverse the inhibitory effect of 10 µM sildenafil on KCl-induced contractility was studied. During this phase of the study, for each mounted myometrial strip, the contractile response to 55 mM KCl was obtained followed by that to KCl in the presence of 10 µM sildenafil. After adequate washes and reaching the baseline, the response to 55 mM KCl and then KCl in the presence of 100 nM iberiotoxin and 10 µM sildenafil was obtained. The concentrations of reversal agents used in this study are those that have been used in previous studies.[11,15-17]

**Statistical analysis**

Contractility was quantified by the maximum height of contraction and the area under the contractile curve (AUCC), a method which has been standardized in our laboratory.[13,14] These parameters were determined by scanning the tracings after each experiment and analysis with the software Image Tool (University of Texas Health Sciences Center at San Antonio, TX, USA). This was done by comparing statistically the values of these parameters of the control data (after the administration of KCl alone) and the values of the test data (after the administration of the test drug (s) with KCl). The nonparametric test, Wilcoxon signed rank test, was used for all statistical analyses of the data.

**RESULTS**

Ten patients who fulfilled the selection criteria were enrolled into the first phase of the study. Their ages ranged from 35 to 50 years with a mean age of 43 years. The clinical diagnoses of the patients were: Fibroids, five patients; endometrial polyp, one patient; pelvic organ prolapse, two patients; adenomyosis, one patient; and simple hyperplasia, one patient. Ten patients who fulfilled the selection criteria were enrolled into the second phase of the study. Their ages ranged from 36 to 49 years with a mean age of 42 years. The clinical diagnoses of these patients were: Fibroids, 8 patients; endometriosis, 1 patient; and adenomyosis, 1 patient. In order to ensure, as much as possible, that all myometrial specimens used in the study had similar physiological conditions, all the specimens were obtained from patients fulfilling the following criteria: Non-pregnant, non-lactating, pre-menopausal patients 20 to 50 years old with non-malignant conditions.

The results of the effect of DMSO and sildenafil on KCl-induced contractility of isolated non-pregnant human myometrium are shown in Table 1. As shown, DMSO did not significantly inhibit KCl-induced myometrial contractility, whereas sildenafil produced a concentration-dependent inhibitory effect of KCl-induced myometrial contractility that was statistically significant at all three concentrations of sildenafil used. The results of the effects of the reversal agents on sildenafil-induced myometrial relaxation are shown in Tables 2 and 3. ODQ and MDL-12,330 A were not found to reverse the inhibitory effect of sildenafil on KCl-induced myometrial contractility. TEA partially reversed the inhibitory effect of sildenafil on myometrial contractility. Iberiotoxin completely and significantly reversed the inhibitory effect of sildenafil on myometrial contractility. Sample tracings of the effect of sildenafil on KCl-induced myometrial contractility and the effects of the reversal agents on 10 µM sildenafil’s inhibition of KCl-induced myometrial contractility are shown in Figures 1 and 2.

**DISCUSSION**

This study has shown for the first time that sildenafil inhibits the contractility of isolated non-pregnant human myometrium [Table 1; Figures 1 and 2]. Although these findings cannot be directly extrapolated to the pregnant human myometrium, they support those of previous studies that have shown that sildenafil inhibits the contractility of isolated pregnant human myometrium.[11,17] In the first phase of this study, it was found that the guanylyl cyclase inhibitor ODQ did not reverse the inhibitory effect of 10 µM sildenafil on KCl-induced myometrial contractility [Table 2]. The adenyl cyclase inhibitor MDL-12,330A also acted like ODQ in this regard, and did not reverse the inhibition of myometrial contractility due to sildenafil [Table 2]. In this context, sildenafil is a specific inhibitor of PDE5, a PDE isozyme that specifically catalyzes the metabolism of cGMP, without catalyzing the metabolism of cAMP.[18] In vitro studies conducted previously have shown that PDE5 is present in the human myometrium.[19,20]
Table 1: Percent inhibition of DMSO and sildenafil of KCl-induced contractility of isolated non-pregnant human myometrium (n=10 for each drug administration)

| Drug Administration                  | % Inhibition of height | % Inhibition of AUCC |
|--------------------------------------|------------------------|----------------------|
|                                      | Mean (SEM)             | P                     | Mean (SEM) | P              |
| 55 mM KCl+DMSO (0.25 ml)             | –0.75 (1.34)           | 0.912                | –0.29 (4.35) | 0.845          |
| 55 mM KCl+3 µM sildenafil             | 19.72 (4.94)           | 0.001                | 25.91 (5.63) | 0.000          |
| 55 mM KCl+10 µM sildenafil            | 36.39 (3.41)           | 0.000                | 48.51 (5.33) | 0.000          |
| 55 mM KCl+30 µM sildenafil            | 57.55 (6.74)           | 0.000                | 74.16 (3.68) | 0.000          |

Values of percent inhibition are compared with those following prior administration of KCl only. AUCC = Area under contractile curve, DMSO = Dimethyl sulfoxide, SEM = Standard error of mean.

Table 2: Effects of reversal agents on 10 µM sildenafil’s inhibition of KCl-induced contractility of isolated non-pregnant human myometrium (n=10 for each drug administration)

| Drug administration                  | % Inhibition of height | % Inhibition of AUCC |
|--------------------------------------|------------------------|----------------------|
|                                      | Mean (SEM)             | P                     | Mean (SEM) | P              |
| 10 µM ODQ+10 µM sildenafil+55 mM KCl | 54.97 (6.33)           | 54.32 (9.36)          |
| 10 µM MDL-12,330A+10 µM sildenafil+55 mM KCl | 58.44 (5.29)        | 67.34 (5.06)          |
| 2 mM TEA+10 µM sildenafil+55 mM KCl  | 17.70 (2.31)           | 16.38 (4.12)          |

Values of percent inhibition are compared with those following prior administration of KCl only. AUCC = Area under contractile curve, SEM = Standard error of mean. TEA = Tetraethyl ammonium. See table 1 for effect of 10 µM sildenafil on KCl-induced myometrial contractility in the absence of reversal agents.

Table 3: Effect of iberiotoxin on 10 µM sildenafil’s inhibition of KCl-induced contractility of isolated non-pregnant human myometrium (n=10 for each drug administration)

| Drug administration                  | % Inhibition of height | % Inhibition of AUCC |
|--------------------------------------|------------------------|----------------------|
|                                      | Mean (SEM)             | P                     | Mean (SEM) | P              |
| 55 mM KCl+10 µM sildenafil            | 21.17 (5.61)           | 0.006                | 40.58 (4.99) | 0.002          |
| 55 mM KCl+100 nM iberiotoxin+10 µM sildenafil | –6.17 (10.23)       | 0.23*                | –5.44 (10.41) | 0.922*         |

Values of percent inhibition are compared with those following prior administration of KCl only. AUCC = Area under contractile curve. *The mean values of percent inhibition are negative since the mean values after addition of iberiotoxin, sildenafil and KCl exceeded those after addition of KCl only.

The non-specific potassium channel blocker TEA partially reversed the inhibitory effect of sildenafil on KCl-induced myometrial contractility during the first phase of this study [Table 2]. This suggests that the opening of cell membrane-bound potassium channels was involved in the mechanism of action of sildenafil. During the second phase of this study, the specific BKCa channel blocker...
iberiotoxin\textsuperscript{21} completely and significantly [Table 3] reversed the inhibitory effect of sildenafil on myometrial contractility, suggesting that the type of potassium channel opened by the administration of sildenafil was the BKCa channel. Iberiotoxin has been shown to reverse the relaxant effect of sildenafil previously in the human detrusor,\textsuperscript{10}\textsuperscript{10} the rabbit ductus arteriosus,\textsuperscript{22}\textsuperscript{22} and penile resistance arteries.\textsuperscript{23}\textsuperscript{23} There is experimental evidence from previous studies on isolated smooth muscles that sildenafil can directly open potassium channels without the need for raised cellular levels of cGMP.\textsuperscript{24,25}\textsuperscript{24,25} In the first phase of our study, the guaneryl cyclase inhibitor ODQ did not reverse the inhibitory effect of sildenafil, suggesting that cGMP was not involved in the inhibitory effect of sildenafil on the myometrium in our study [Table 2]. BKCa channels are abundant in the human myometrium and are known to play a major role in myometrial contractility.\textsuperscript{26,27}\textsuperscript{26,27} There is also evidence that the myometrium is different from other tissues in that BKCa channels in the myometrium can function independently of cGMP.\textsuperscript{28}\textsuperscript{28} Alternatively, since cGMP can regulate BKCa channels,\textsuperscript{29,30}\textsuperscript{29,30} it is possible that the raised cellular levels of cGMP due to inhibition of PDE5 by sildenafil could have opened the BKCa channels.

**CONCLUSION**

In conclusion, this study has shown that suitably low concentrations of sildenafil inhibit the contractility of the isolated non-pregnant human myometrium. The results suggest that the likely mechanism involved is the opening of BKCa channels. The results suggest that sildenafil has the potential to be used in clinical conditions like preterm labor requiring inhibition of myometrial contractility.

**Acknowledgements**

This study was funded by an intramural research grant. The authors acknowledge Mrs. J Sudha for help with data analysis.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Hatzimouratidis K. Sildenafil in the treatment of erectile dysfunction: An overview of the clinical evidence. Clin Interv Aging 2006;1:403-14.
2. Ramani GV, Park MH. Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension. Drug Des Devel Ther 2010;4:61-70.
3. Buolll M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, et al. Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996;8:47-52.
4. Bruzziches R, Francomeno D, Gareri P, Lenzi A, Aversa A. An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors. Expert Opin Pharmacother 2013;14:1333-44.
5. Medina P, Segerra G, Torondel B, Chuan P, Domenech C, Vila JM, et al. Inhibition of neuroeffector transmission in human vas deferens by sildenafil. Br J Pharmacol 2000;131:871-4.
6. Chuang AT, Strauss JD, Murphy RA, Steers WD. Sildenafil, a type-5 phosphodiesterase inhibitor, specifically amplifies endogenous cGMP-dependent relaxation in rabbit corpus cavernosum smooth muscle in vitro. J Urol 1998;160:257-61.
7. Biau J, Dufourmeil C, Prouvost V, Coupres JL, Coudray A, et al. Sildenafil reduces the contractile response of the human corpus cavernosum in vitro. J Int Med Res 2001;29:475-82.
8. Yuan Z, Hein TW, Rosa RH Jr, Kuo L, Sildenafil (Viagra) evokes retinal arteriolar dilation: Dual pathways via NOS activation and phosphodiesterase inhibition. Invest Ophthalmol Vis Sci 2008;49:720-5.
9. Clemente CM, Araujo PV, Palmetto RC Jr, Ratts ZM, Fernandes GH, Rola FH, et al. Sildenafil inhibits duodenal contractility via activation of the NO-K+ channel pathway. Fundam Clin Pharmacol 2008;22:617-24.
10. Oger S, Berh-Roussel D, Gorny D, Lefevre T, Valérie P, Catherineau X, et al. Signalling pathways involved in sildenafil-induced relaxation of human bladder dome smooth muscle. Br J Pharmacol 2010;160:3115-21.
11. Khan RN, Hamoud H, Warren A, Wong LF, Arulkumaran S. Relaxant action of sildenafil citrate (Viagra) on human myometrium of pregnancy. Am J Obstet Gynecol 2004;191:315-21.
12. Chiossi G, Costantine MM, Betancourt A, Hanks KD, Longo M, Saade GR, et al. Does sildenafil citrate affect myometrial contractile response to nifedipine in vitro? Am J Obstet Gynecol 2010;203:252.e1-5.
13. Prabhakaran SS, Dhanasekar KR, Thomas E, Jose R, Peciciayl J, Samuel P. Inhibition of isolated human myometrium contractility by minoxidil and reversal by gluthenamide. Methods Find Exp Clin Pharmacol 2010;32:97-100.
14. Shah NH, Thomas E, Jose R, Peciclayl J. Tramadol inhibits the contractility of isolated human myometrium. Auton Autacoid Pharmacol 2013;33:1-5.
15. Vila-Petroff MG, Younes A, Egan J, Lakatta EG, Sollott SJ. Activation of distinct cAMP-dependent and cGMP-dependent pathways by nitric oxide in cardiac myocytes. Circ Res 1999;84:1020-31.
16. Li X, Guo Q, Gao J, Yang J, Zhang W, Liang Y, et al. The adenylyl cyclase inhibitor MDL-12,330A potentiates insulin secretion via blockade of voltage-dependent K(+) channels in pancreatic beta cells. PLoS One 2013;8:e77934.
17. Walker SD, Dora KA, Ings NT, Crane GJ, Garland CJ. Activation of endothelial cell IK (Ca) with 1-ethyl-2-benzimidazolinone evokes smooth muscle hyperpolarization in rat mesenteric artery. Br J Pharmacol 2001;134:1548-54.
18. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use. Pharmacol Rev 2006;58:488-520.
19. Belmonte A, Ticconi C, Dolci S, Giorgi M, Zacari A, Lenzi A, et al. Regulation of phosphodiesterase 5 expression and activity in human pre¬pregnant and non-pregnant myometrial cells by human chorionic gonadotropin. J Soc Gynecol Investig 2005;12:570-7.
20. Dolci S, Belmonte A, Santone R, Giorgi M, Pellegrini M, Carosa E, et al. Subcellular localization and regulation of type-1C and type-5 phosphodiesterases. Biochim Biophys Acta 2006;1765:837-46.
21. Candia S, Garcia ML, Latorre R. Mode of action of iberiotoxin, a potent blocker of the large conductance Ca (2+)-activated K+ channel. Biophys J 1992;63:583-90.
22. Theloud B, Michalakis E, Wu XC, Harry G, Hashimoto K, Archer SL. Sildenafil reverses Ca2+-activated K+ channel. Biophys J 1998;75:2117-27.
23. Prieto D, Rivera L, Benedito S, Recio P, Villalba N, Hernandez M, et al. Ca2+ -activated K+ (KCa) channels are involved in the relaxations elicited by sildenafil in penile resistance arteries. Eur J Pharmacol 2006;531:212-7.
24. Medina P, Segarra G, Torondel B, Chuan P, Domenech C, Vila JM, et al. Inhibition of neuroeffector transmission in human vas deferens by sildenafil. Br J Pharmacol 2000;131:871-4.
25. El-Metwally MA, Sharabi FM, Daabees TT, Senbel AM, Mostafa T. Involvement of alpha-receptors and potassium channels in the mechanism of action of sildenafil citrate. Int J Impot Res 2007;19:551-7.
26. Khan RN, Matharoo-Ball B, Arulkumaran S, Ashford ML. Potassium channels in the human myometrium. Exp Physiol 2001;86:255-64.
27. Brainard AM, Korovkina VP, England SK. Potassium channels and uterine function. Semin Cell Dev Biol 2007;18:332-9.
28. Buxton IL. Regulation of uterine function: A biochemical conundrum in the regulation of smooth muscle relaxation. Mol Pharmacol 2004;65:1051-9.
29. Zhou XB, Arutz C, Kamm S, Motiejuk K, Saubier U, Wang GX, et al. A molecular switch for specific stimulation of the BKCa channel by cGMP and cAMP kinase. J Biol Chem 2001;276:43239-45.
30. Schubert R, Nelson MT. Protein kinases: Turners of the BKCa channel in smooth muscle. Trends Pharmacol Sci 2001;22:505-12.